Kopion Asset Management LLC Grows Holdings in Certara, Inc. (NASDAQ:CERT)

Kopion Asset Management LLC increased its holdings in Certara, Inc. (NASDAQ:CERT) by 46.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 555,643 shares of the company’s stock after purchasing an additional 175,005 shares during the period. Certara accounts for 4.2% of Kopion Asset Management LLC’s investment portfolio, making the stock its 14th biggest position. Kopion Asset Management LLC owned about 0.35% of Certara worth $5,918,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Blue Trust Inc. grew its holdings in Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after purchasing an additional 2,076 shares during the period. KBC Group NV raised its holdings in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the period. GAMMA Investing LLC grew its holdings in shares of Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after purchasing an additional 6,868 shares during the period. Intech Investment Management LLC acquired a new stake in Certara during the 2nd quarter worth approximately $152,000. Finally, Algert Global LLC acquired a new position in Certara during the second quarter valued at approximately $156,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Price Performance

Shares of CERT stock traded up $0.53 during mid-day trading on Wednesday, hitting $11.27. 104,860 shares of the stock traded hands, compared to its average volume of 785,986. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company’s 50-day simple moving average is $10.86 and its 200-day simple moving average is $11.95. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -56.35, a price-to-earnings-growth ratio of 5.86 and a beta of 1.52.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the prior year, the company earned $0.06 earnings per share. The firm’s revenue was up 10.7% on a year-over-year basis. As a group, equities research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CERT shares. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Barclays reduced their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Finally, Robert W. Baird lowered their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.